{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:40:04Z","timestamp":1791121204428,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10549-012-2222-2","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T03:24:42Z","timestamp":1346124282000},"page":"771-780","source":"Crossref","is-referenced-by-count":33,"title":["RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model"],"prefix":"10.1007","volume":"135","author":[{"given":"Jude","family":"Canon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Roudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Branstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"issue":"8 Suppl","key":"2222_CR1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588\u20131594","journal-title":"Cancer"},{"issue":"4","key":"2222_CR2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.bjc.6601198","volume":"89","author":"JJ James","year":"2003","unstructured":"James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JF (2003) Bone metastases from breast carcinoma: histopathological\u2013radiological correlations and prognostic features. Br J Cancer 89(4):660\u2013665. doi: 10.1038\/sj.bjc.6601198","journal-title":"Br J Cancer"},{"issue":"1","key":"2222_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH Zhang","year":"2009","unstructured":"Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1):67\u201378. doi: 10.1016\/j.ccr.2009.05.017","journal-title":"Cancer Cell"},{"issue":"22","key":"2222_CR4","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925\u20134935","journal-title":"J Clin Oncol"},{"issue":"1","key":"2222_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1):59\u201369","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2222_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"2222_CR7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"issue":"1","key":"2222_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ncponc0381","volume":"3","author":"JM Blair","year":"2006","unstructured":"Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3(1):41\u201349","journal-title":"Nat Clin Pract Oncol"},{"issue":"11","key":"2222_CR9","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61(11):4432\u20134436","journal-title":"Cancer Res"},{"issue":"2","key":"2222_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119\u2013129. doi: 10.1007\/s10585-007-9127-1","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"2222_CR11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bone.2010.03.001","volume":"46","author":"J Canon","year":"2010","unstructured":"Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC (2010) Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46(6):1613\u20131619. doi: 10.1016\/j.bone.2010.03.001","journal-title":"Bone"},{"issue":"7","key":"2222_CR12","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","volume":"7","author":"RE Miller","year":"2008","unstructured":"Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC (2008) RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 7(7):2160\u20132169","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2222_CR13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107(10):1235\u20131244","journal-title":"J Clin Invest"},{"key":"2222_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10585-006-9008-z","volume":"23","author":"SH Tannehill-Gregg","year":"2006","unstructured":"Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ (2006) The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 23:19\u201331","journal-title":"Clin Exp Metastasis"},{"issue":"19","key":"2222_CR15","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","volume":"27","author":"K Visvanathan","year":"2009","unstructured":"Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235\u20133258. doi: 10.1200\/JCO.2008.20.5179","journal-title":"J Clin Oncol"},{"issue":"19","key":"2222_CR16","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1128\/MCB.01745-08","volume":"29","author":"AJ Finch","year":"2009","unstructured":"Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI (2009) Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt\/beta-catenin pathway activation. Mol Cell Biol 29(19):5306\u20135315. doi: 10.1128\/MCB.01745-08","journal-title":"Mol Cell Biol"},{"issue":"13","key":"2222_CR17","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1074\/jbc.M110.188797","volume":"286","author":"TH Kim","year":"2011","unstructured":"Kim TH, Shivdasani RA (2011) Genetic evidence that intestinal Notch functions vary regionally and operate through a common mechanism of Math1 repression. J Biol Chem 286(13):11427\u201311433","journal-title":"J Biol Chem"},{"issue":"1","key":"2222_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1022166517963","volume":"78","author":"KR Hess","year":"2003","unstructured":"Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105\u2013118","journal-title":"Breast Cancer Res Treat"},{"issue":"7320","key":"2222_CR19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103\u2013107. doi: 10.1038\/nature09495","journal-title":"Nature"},{"issue":"7320","key":"2222_CR20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","volume":"468","author":"D Schramek","year":"2010","unstructured":"Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98\u2013102","journal-title":"Nature"},{"issue":"20 Pt 2","key":"2222_CR21","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s\u20136249s. doi: 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2222_CR22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.9.7.11266","volume":"9","author":"PM Holland","year":"2010","unstructured":"Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC (2010) Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L\/TRAIL\/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9(7):539\u2013550. doi: 11266 [pii]","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"2222_CR23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.20744","volume":"68","author":"KM Ignatoski","year":"2008","unstructured":"Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET (2008) RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 68(8):820\u2013829","journal-title":"Prostate"},{"issue":"35","key":"2222_CR24","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132\u20135139. doi: 10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"2222_CR25","author":"MR Smith","year":"2011","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2011) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. doi: 10.1016\/S0140-6736(11)61226-9","journal-title":"Lancet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2222-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2222-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2222-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:34:06Z","timestamp":1559219646000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2222-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2222-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}